Search results for "immunotherapy"

showing 10 items of 830 documents

Thyroïdites : où en est-on en 2019 ?

2020

Thyroiditis is a frequent and mostly benign disease that can sometimes disrupt the thyroid balance. Their diagnosis, as well as their aetiology, is a necessary step in the management of the patients. Painful thyroiditis includes acute thyroiditis of infectious origin and subacute thyroiditis. The first one can be treated by antibiotics or antifungals depending on the germ found. The second one will be treated with non-steroidal anti-inflammatory drugs or corticosteroids. In cases of Hashimoto's thyroiditis with overt hypothyroidism, replacement therapy with L-thyroxine will be adapted to the TSH level. As amiodarone treatment provides dysthyroidism, the thyroid status should be monitored re…

endocrine systemPediatricsmedicine.medical_specialtyendocrine system diseasesmedicine.medical_treatment[SDV]Life Sciences [q-bio]030209 endocrinology & metabolismContext (language use)AmiodaroneThyroiditis03 medical and health sciences0302 clinical medicineInternal MedicinemedicineSubacute thyroiditisbusiness.industryThyroid diseaseThyroidGastroenterologyImmunotherapymedicine.disease3. Good health[SDV] Life Sciences [q-bio]medicine.anatomical_structure030220 oncology & carcinogenesisEtiologybusinesshormones hormone substitutes and hormone antagonistsmedicine.drug
researchProduct

Retrieval of functional TCRs from single antigen-specific T cells: Toward individualized TCR-engineered therapies

2015

We have developed a highly versatile platform for the systematic retrieval of T-cell receptors (TCRs) from single-antigen-reactive T cells and for characterization of their function and specificity. This approach enables rapid extraction of multiple TCRs from repertoires in individuals and not only broadens the diversity of TCRs suitable for clinical use, but also sets the stage for actively personalized immunotherapeutic strategies.

epitopeAdoptive cell transferImmunologyT-cell receptorhemic and immune systemschemical and pharmacologic phenomenaComputational biologyBiologypersonalized immunotherapybiological factorsEpitopeOncologyAntigen specificImmunologyImmunology and AllergyT cell engineeringT cell receptorAuthor's Viewtissuesadoptive cell transferOncoImmunology
researchProduct

Anti-inflammatory effects of pre-seasonal Th1-adjuvant vaccine to Parietaria judaica in asthmatics

2011

Nicola Scichilone, Chiara Minaldi, Roberta Santagata, Salvatore Battaglia, Gaetana Camarda, Vincenzo Bellia Dipartimento Biomedico di Medicina Interna e Specialistica (Di.Bi.M.I.S.), Sezione di Pneumologia, University of Palermo, Palermo, ItalyBackground: The ultra-short course pre-seasonal allergy vaccine, containing appropriate allergoids with the adjuvant monophosphoryl lipid A (MPL), may be effective in treating allergic symptoms. Objective: To explore the timing of the immunological responses to the pre-seasonal allergy vaccine.Methods: Four subcutaneous injections of the active product (Pollinex Quattro) were administered to 20 Parietaria-sensitive intermittent asthmatics (M/F: 12/8; …

exhaled breath condensatelcsh:Immunologic diseases. AllergyPulmonary and Respiratory MedicinePediatricsmedicine.medical_specialtymedicine.drug_classmedicine.medical_treatmentSettore MED/10 - Malattie Dell'Apparato Respiratoriomedicine.disease_causeAnti-inflammatoryAllergenJournal of Asthma and AllergymedicineImmunology and AllergyExhaled breath condensateOriginal ResearchAsthmabiologybusiness.industryasthmabiology.organism_classificationmedicine.diseaseinflammationpollenallergen asthma immunotherapy inflammation pollen exhaled breath condensateImmunologyParietaria judaicaimmunotherapylcsh:RC581-607businessAdjuvantallergenJournal of Asthma and Allergy
researchProduct

V gamma 9V delta 2 T lymphocytes efficiently recognize and kill zoledronate-sensitized, imatinib-sensitive, and imatinib-resistant chronic myelogenou…

2010

Abstract Imatinib mesylate (imatinib), a competitive inhibitor of the BCR-ABL tyrosine kinase, is highly effective against chronic myelogenous leukemia (CML) cells. However, because 20–30% of patients affected by CML display either primary or secondary resistance to imatinib, intentional activation of Vγ9Vδ2 T cells by phosphoantigens or by agents that cause their accumulation within cells, such as zoledronate, may represent a promising strategy for the design of a novel and highly innovative immunotherapy capable to overcome imatinib resistance. In this study, we show that Vγ9Vδ2 T lymphocytes recognize, trogocytose, and efficiently kill imatinib-sensitive and -resistant CML cell lines pre…

gamma delta T cells Imatinib Leukemia cellsAdultmedicine.medical_treatmentImmunologyMice SCIDLymphocyte ActivationZoledronic AcidPiperazinesMicehemic and lymphatic diseasesLeukemia Myelogenous Chronic BCR-ABL PositivemedicineImmunology and AllergyAnimalsHumansneoplasmsCells CulturedDiphosphonatesbusiness.industryImidazolesImatinibReceptors Antigen T-Cell gamma-deltaImmunotherapymedicine.diseaseIn vitroCoculture TechniquesDrug Resistance MultipleLeukemiaImatinib mesylatePyrimidinesCell cultureDrug Resistance NeoplasmImmunologyBenzamidesCancer researchImatinib MesylatebusinessK562 CellsTyrosine kinasemedicine.drugChronic myelogenous leukemiaT-Lymphocytes CytotoxicJournal of immunology (Baltimore, Md. : 1950)
researchProduct

gammadelta T Cell Modulation in Anticancer Treatment

2010

The broad antimicrobial and antitumoral reactivity of Vgamma9Vdelta2 T cells, their ability to produce inflammatory cytokines involved in protective immunity against intracellular pathogens and tumors and their strong cytolytic and bactericidal activities suggest their direct involvement in immune control of cancers and infections. gammadelta T cells can be selectively activated by naturally occurring or synthetic phosphoantigens, and drugs that enhance their accumulation into stressed cells, offering new avenues for the development of gammadelta T cell-based immunotherapies. The recent development of small drugs selectively activating Vgamma9Vdelta2 T lymphocytes, which upregulate endogeno…

gamma delta T cells immunotherapy cancer
researchProduct

Heterogeneity and prognostic influence of tumor-infiltrating gamma-delta T lymphocytes in colon cancer patients

2013

gamma-delta T cells Colon Cancer immunosurveillance Immunotherapy tumor immunitybusiness.industryColorectal cancerImmunologyCancer researchMedicineImmunology and Allergybusinessmedicine.diseaseFrontiers in Immunology
researchProduct

Moving Immune Checkpoint Inhibitors to Early Non-Small Cell Lung Cancer: A Narrative Review

2022

Simple Summary Moving from the achievements of immune checkpoint inhibitors in metastatic lung cancer, the great promise of immunotherapy in resectable early-stage is to make a disease, often lethal until now for frequent post-surgery relapses, more curable. This review focuses on role of immunotherapy in early-stage non-small cell lung cancer. We summarize biological rationale, findings from clinical trials of adjuvant and neoadjuvant immune checkpoint inhibitors, questions about biomarkers and choice of endpoints, aiming to provide up-to-date information useful for clinical decision making. Lung cancer is the leading cause of cancer-related death worldwide. Since prognosis of early-stage …

immune checkpoint inhibitorsCancer Researchlung cancernon-small-cell lung carcinoma (NSCLC)OncologyadjuvantSettore MED/06 - Oncologia Medicaneoadjuvantadjuvant; immune checkpoint inhibitors; immunotherapy; lung cancer; neoadjuvant; non-small-cell lung carcinoma (NSCLC);immune checkpoint inhibitorimmunotherapy
researchProduct

The Application of CRISPR/Cas9 Technology for Cancer Immunotherapy: Current Status and Problems

2022

Cancer is one of the main causes of disease-related deaths in the world. Although cancer treatment strategies have been improved in recent years, the survival time of cancer patients is still far from satisfied. Cancer immunotherapy, such as Oncolytic virotherapy, Immune checkpoints inhibition, Chimeric antigen receptor T (CAR-T) cell therapy, Chimeric antigen receptor natural killer (CAR-NK) cell therapy and macrophages genomic modification, has emerged as an effective therapeutic strategy for different kinds of cancer. However, many patients do not respond to the cancer immunotherapy which warrants further investigation to optimize this strategy. The clustered regularly interspaced short …

immune checkpoints inhibitionCancer ResearchOncologyoncolytic virusesMini ReviewcancerNeoplasms. Tumors. Oncology. Including cancer and carcinogensimmunotherapyCAR-T therapyCRISPR/Cas9RC254-282Frontiers in Oncology
researchProduct

Effects of B-Cell Lymphoma on the Immune System and Immune Recovery after Treatment: The Paradigm of Targeted Therapy

2022

B-cell lymphoma and lymphoproliferative diseases represent a heterogeneous and complex group of neoplasms that are accompanied by a broad range of immune regulatory disorder phenotypes. Clinical features of autoimmunity, hyperinflammation, immunodeficiency and infection can variously dominate, depending on the immune pathway most involved. Immunological imbalance can play a role in lymphomagenesis, also supporting the progression of the disease, while on the other hand, lymphoma acts on the immune system to weaken immunosurveillance and facilitate immunoevasion. Therefore, the modulation of immunity can have a profound effect on disease progression or resolution, which makes the immune syst…

immunosenescenceLymphoma B-CellimmunosuppressionLymphomaB-cell lymphomaOrganic ChemistryGeneral Medicineimmune recoverychemotherapytargeted therapyImmunotherapy AdoptiveLymphoproliferative DisordersCatalysisComputer Science ApplicationsCAR-TSettore MED/15 - Malattie Del SangueInorganic ChemistryImmune Systemimmune therapyTumor MicroenvironmentimmunoevasionHumansPhysical and Theoretical ChemistryMolecular BiologySpectroscopy
researchProduct

Classification of current anticancer immunotherapies.

2014

© 2014. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

immunostimulatory cytokinesmedicine.medical_treatmentReviewBioinformaticsDNA-based vaccinesEfficacy0302 clinical medicineCancer immunotherapyNeoplasmspeptide-based vaccines0303 health sciencesPatología//purl.org/becyt/ford/3.1 [https]CANCER3. Good healthMedicina BásicaOncologycheckpoint blockers030220 oncology & carcinogenesisQR180//purl.org/becyt/ford/3 [https]ImmunotherapyCIENCIAS MÉDICAS Y DE LA SALUDmedicine.drug_classInmunologíaadoptive cell transfer; checkpoint blockers; dendritic cell-based interventions; DNA-based vaccines; immunostimulatory cytokines; peptide-based vaccines; oncolytic viruses; Toll-like receptor agonistsMonoclonal antibodydendritic cell-based interventionsToll-like receptor agonistsRC025403 medical and health sciencesImmune systemAntigen[SDV.BBM] Life Sciences [q-bio]/Biochemistry Molecular BiologymedicineAnimalsHumans[SDV.BBM]Life Sciences [q-bio]/Biochemistry Molecular Biology[ SDV.BBM ] Life Sciences [q-bio]/Biochemistry Molecular Biologyadoptive cell transfer030304 developmental biologyIMMUNOTHERAPIESbusiness.industryCancerImmunotherapymedicine.diseaseR1Oncolytic virusoncolytic virusesImmunologybusinessOncotarget
researchProduct